학술논문
Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia
Document Type
article
Author
Youjin Wang; Weiyin Zhou; Lisa J. McReynolds; Hormuzd A. Katki; Elizabeth A. Griffiths; Swapna Thota; Mitchell J. Machiela; Meredith Yeager; Philip McCarthy; Marcelo Pasquini; Junke Wang; Ezgi Karaesmen; Abbas Rizvi; Leah Preus; Hancong Tang; Yiwen Wang; Loreall Pooler; Xin Sheng; Christopher A. Haiman; David Van Den Berg; Stephen R. Spellman; Tao Wang; Michelle Kuxhausen; Stephen J. Chanock; Stephanie J. Lee; Theresa E. Hahn; Lara E. Sucheston-Campbell; Shahinaz M. Gadalla
Source
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Subject
Language
English
ISSN
2045-2322
24378046
24378046
Abstract
Abstract To improve risk stratification and treatment decisions for patients with acute myeloid leukemia (AML) undergoing hematopoietic cell transplantation (HCT). We used SNP-array data from the DISCOVeRY-BMT study to detect chromosomal aberrations in pre-HCT peripheral blood (collected 2–4 weeks before the administration of conditioning regimen) from 1974 AML patients who received HCT between 2000 and 2011. All aberrations detected in ≥ 10 patients were tested for their association with overall survival (OS), separately by remission status, using the Kaplan–Meier estimator. Cox regression models were used for multivariable analyses. Follow-up was through January 2019. We identified 701 unique chromosomal aberrations in 285 patients (7% of 1438 in complete remission (CR) and 36% of 536 not in CR). Copy-neutral loss-of-heterozygosity (CNLOH) in chr17p in CR patients (3-year OS = 20% vs. 50%, with and without chr17p CNLOH, p = 0.0002), and chr13q in patients not in CR (3-year OS = 4% vs. 26%, with and without chr13q CNLOH, p